All In Biotech

Drug Trial Radar · NCT03107611

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® (Pimecrolimus) Cream, 1% in Patients With Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

654

Actual

Start

Feb 29, 2016

Primary completion

May 15, 2017

Study completion May 15, 2017

Sponsor

Lead sponsor
Mylan Inc.Industry
Sponsor type
Industry
Collaborators
DPT Laboratories, Ltd.
First posted
Apr 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate Atopic Dermatitis. To establish superiority of each active treatment over the placebo.

Conditions

  • Atopic Dermatitis

Interventions

  • Pimecrolimus Cream, 1%Drug

  • Placebo CreamDrug

  • Pimecrolimus Cream, 1%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])Time frame: Day 15
  2. Proportion of Per Protocol Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])Time frame: Day 15

Locations

27 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Facility 6

    Boynton Beach, Florida

  • Research Facility 4

    Coral Gables, Florida

  • Research Facility 5

    Miami, Florida

  • Research Facility 10

    Miami, Florida

  • Research Facility 1

    Miami Lakes, Florida

  • Research Facility 9

    Miramar, Florida

  • Research Facility 33

    Sweetwater, Florida

  • Research Facility 23

    Boise, Idaho

  • Research Facility 28

    Overland Park, Kansas

  • Research Facility 32

    Louisville, Kentucky

  • Research Facility 13

    New Orleans, Louisiana

  • Research Facility 7

    Saint Joseph, Missouri

  • Research Facility 19

    Omaha, Nebraska

  • Research Facility 29

    Albuquerque, New Mexico

  • Research Facility 24

    Charlotte, North Carolina

  • Research Facility 2

    High Point, North Carolina

  • Resarch Facility 8

    Philadelphia, Pennsylvania

  • Research Facility 18

    Johnston, Rhode Island

  • Research Facility 20

    Austin, Texas

  • Research Facility 16

    College Station, Texas

  • Research Facility 31

    Pflugerville, Texas

  • Research Facility 17

    Sugar Land, Texas

  • Research Facility 22

    West Jordan, Utah

  • Research Facility 15

    Richmond, Virginia

  • Research Facility 26

    Spokane, Washington

  • Research Facility 11

    Santo Domingo, Dominican Republic

  • Research Facility 12

    San Pedro Sula, Honduras

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.